MICB: A Multi-Functional Protein in The MHC Class I Molecules

Target Name: MICB

NCBI ID: G4277

MICB

MICB: A Multi-Functional Protein in The MHC Class I Molecules

MICB, or MHC class I polypeptide-related sequence B (isoform 1), is a protein that is expressed in the major histocompatibility complex (MHC) class I molecules. The MHC is a protein complex that is present in most tissues throughout the body, including the skin, hair, nails, and connective tissue. The MHC is involved in the immune response, as it presents antigens to T cells so that they can recognize and attack foreign substances in the body.

One of the unique features of MICB is its structure. MICB is a transmembrane protein, meaning that it spans the entire thickness of the cell membrane. It consists of a long amino acid sequence that is capped at its C-terminus by a unique glycophorin, which is a protein that can interact with certain types of ions in the cell. The N-terminus of MICB contains a variable region that is involved in its interactions with other proteins.

MICB has several potential functions as a drug target or biomarker. One of the main functions of MICB is its role in the immune response. MICB is a key player in the presentation of antigens to T cells, which is the first step in the immune response. MICB helps to recruit T cells to the site of an antigen, and it also helps to ensure that the antigens are processed and loaded onto the T cells so that they can be recognized by the cell.

Another potential function of MICB is its role in cancer. MICB has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the development and progression of cancer. For example, studies have shown that MICB can be overexpressed in cancer cells, which can lead to the development of an aggressive cancer.

In addition to its potential role in cancer, MICB may also be a useful biomarker for some types of cancer. For example, some studies have shown that MICB can be used as a marker for the efficacy of anti-cancer drugs in breast cancer. This is because MICB is often expressed in the cells that are targeted by these drugs, and the levels of MICB in these cells can be used to track the effectiveness of the drug.

MICB is also a potential drug target for itself. Studies have shown that MICB can interact with a variety of different drugs, including small molecules and antibodies. This makes it a promising target for the development of new drugs for cancer and other diseases. For example, researchers have shown that MICB can be targeted with small molecules that inhibit its function as a signaling molecule.

In conclusion, MICB is a protein that is expressed in the MHC class I molecules and has several potential functions as a drug target or biomarker. Its role in the immune response and cancer development makes it an attractive target for the development of new drugs. Furthermore, its unique structure and multiple potential functions make it an interesting candidate for further research.

Protein Name: MHC Class I Polypeptide-related Sequence B

Functions: Seems to have no role in antigen presentation. Acts as a stress-induced self-antigen that is recognized by gamma delta T cells. Ligand for the KLRK1/NKG2D receptor. Binding to KLRK1 leads to cell lysis

The "MICB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MICB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets